Karyopharm Therapeutics Inc.
selinexor
myelofibrosis
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on selinexor for myelofibrosis is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“the Company believes that potential inclusion in relevant compendia could occur in the second half of 2026.”